What To Know: CEO Seth Lederman expressed confidence in the drug's potential to introduce a new class of fibromyalgia treatments. The company anticipates a possible launch in Q4 2025, pending FDA approval.
TNX-102 SL, a sublingual formulation of cyclobenzaprine HCl, previously received Fast Track designation in 2024, expediting its regulatory review.
Tonix says, with over 10 million U.S. adults affected by fibromyalgia, the approval of TNX-102 SL could mark a significant advancement in addressing this chronic pain disorder. Tonix remains optimistic about the drug's potential to meet the unmet needs of fibromyalgia patients.
Read Also: Oil Rises As US And Russia Begin Talks In Saudi Arabia For Ukraine Ceasefire, Black Sea Deal
How To Buy TNXP Stock
By now you're likely curious about how to participate in the market for Tonix Pharmaceuticals – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.
In the case of Tonix Pharmaceuticals, which is trading at $23.03 as of publishing time, $100 would buy you 4.34 shares of stock.
According to data from Benzinga Pro, TNXP has a 52-week high of $1,146.01 and a 52-week low of $6.76.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
